Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Endometrial cancer is the fourth most common female cancer in the UK and the most common gynaecological cancer. Quality of life and symptom control needs to be considered in women who enter a surgically induced menopause. Hormone replacement in this population has been controversial to date. The current evidence regarding the safety of estrogen only and combined hormone replacement therapy is discussed in this review. The use of topical vaginal therapies, alternate therapies and the current data regarding testosterone use for symptom control is also outlined.

Original publication

DOI

10.1258/mi.2012.012024

Type

Journal article

Journal

Menopause Int

Publication Date

12/2012

Volume

18

Pages

134 - 138

Keywords

Androgens, Endometrial Neoplasms, Estrogen Replacement Therapy, Estrogens, Female, Hormone Replacement Therapy, Humans, Menopause, Premature, Testosterone, Vaginal Creams, Foams, and Jellies